Claims for Patent: 8,969,569

Summary for Patent: 8,969,569

Title:	Salt and crystalline forms thereof of a drug
Abstract:	A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Inventor(s):	Zhang; Geoff G. Z. (Libertyville, IL), Bradley; Michael F. (Covington, WA), Barnes; David M. (Lake Villa, IL), Henry; Rodger (Wildwood, IL)
Assignee:	AbbVie Inc. (North Chicago, IL)
Application Number:	14/175,621
Patent Claims:	1. A therapeutic composition comprising D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-h- ydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, at least one filler, at least one binder, at least one disintegrating agent, at least one buffering agent and at least one lubricant. 2. The composition of claim 1, wherein the salt is present in a therapeutically acceptable amount. 3. The composition of claim 1, wherein the salt is crystalline. 4. The composition of claim 3, wherein the salt has substantial crystalline purity. 5. The composition of claim 4, wherein the salt has at least about 95% crystalline purity. 6. The composition of claim 3, wherein the salt is characterized, when measured at about 25.degree. C. with Cu-K.alpha. radiation, by the powder diffraction pattern shown in FIG. 1. 7. The composition of claim 3, wherein the salt is characterized by respective lattice parameters, a, b, and c of about 16.4460 .ANG., 21.4010 .ANG., and 5.3050 .ANG. and .beta. of about 109.degree. in the monoclinic crystal system P 21/C or P 21/M space group, when measured with Mo-K.alpha. radiation at about 25.degree. C. 8. The composition of claim 1, wherein the salt has substantial chemical purity. 9. The composition of claim 8, wherein the salt is about 97% chemically pure. 10. The composition of claim 8, wherein the salt is about 98% chemically pure. 11. The composition of claim 8, wherein the salt is about 100% chemically pure. 12. The composition of claim 1, wherein the composition is an orally administered dosage form. 13. The composition of claim 1, wherein the at least one filler comprises cellulose. 14. The composition of claim 1, wherein the at least one binder comprises povidone. 15. The composition of claim 1, wherein the at least one disintegrating agent comprises cross-povidone. 16. The composition of claim 1, wherein the at least one buffering agent comprises a sodium phosphate salt. 17. The composition of claim 1, wherein the at least one buffering agent comprises a citrate. 18. The composition of claim 1, wherein the at least one lubricant comprises magnesium stearate. 19. The composition of claim 1, wherein the at least one filler comprises cellulose, the at least one binder comprises povidone, the at least one disintegrating agent comprises cross-povidone, the at least one buffering agent comprises a sodium phosphate salt, and the at least one lubricant comprises magnesium stearate. 20. The composition of claim 19, further comprising a citrate. 21. A therapeutic composition comprising D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-h- ydroxyazetidin-1-yl) -4-oxo-3-quinolinecarboxylate salt, cellulose, povidone, cross-povidone, a sodium phosphate salt and magnesium stearate. 22. The therapeutic composition of claim 21, further comprising a citrate. 23. A method of treating a bacterial infection in a fish or a mammal comprising administering thereto a composition comprising a therapeutically acceptable amount of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl) -8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinoli- necarboxylate salt, at least one filler, at least one binder, at least one disintegrating agent, at least one buffering agent and at least one lubricant. 24. The method of claim 21, wherein the composition is administered to a mammal. 25. The method of claim 21, wherein the therapeutically acceptable amount is from about 0.03 to about 200 mg/kg body weight. 26. The method of claim 21, wherein the at least one filler comprises cellulose. 27. The method of claim 21, wherein the at least one binder comprises povidone. 28. The method of claim 21, wherein the at least one disintegrating agent comprises cross-povidone. 29. The method of claim 21, wherein the at least one buffering agent comprises a sodium phosphate salt. 30. The method of claim 21, wherein the at least one buffering agent comprises a citrate. 31. The method of claim 21, wherein the at least one lubricant comprises magnesium stearate. 32. The method of claim 21, wherein the at least one filler comprises cellulose, the at least one binder comprises povidone, the at least one disintegrating agent comprises cross-povidone, the at least one buffering agent comprises a sodium phosphate salt, and the at least one lubricant comprises magnesium stearate. 33. The method of claim 32, further comprising a citrate. 34. A method of treating a bacterial infection in a fish or a mammal comprising administering thereto a composition comprising a therapeutically acceptable amount of D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro -7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt, at least one filler, cellulose, povidone, cross-povidone, a sodium phosphate salt and magnesium stearate. 35. The method of claim 34, further comprising a citrate.